| Next 10 |
TRVN News and Press, Trevena Inc.
-
OLINVYK - TRVN's main drug, an opioid painkiller - has a "value proposition" of >10x net savings for hospitals and a high level of initial inbound interest. Potential shortages of IV morphine/hydrocodone in part due to COVID-19 cases is leaving a gap that OLINVYK could potentially ...
-
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate ...
-
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a b...
-
-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P 1 receptor without associated lymphopenia IND filing on track for 1H 2021 -- CHESTERBROOK...
-
Unique Pipelines Could Have These Penny Stocks On The Radar Before 2021 We talked about some biotech penny stocks earlier today and several took flight early. As the markets race to all-time highs once again, it’s no wonder why this sector is on fire. Countless companies are ...
-
-- OLINVYK s ignificantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis -- CHESTERBROOK, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused o...
-
3 Biotech Penny Stocks to Watch in 2020 Biotech penny stocks have become some of the most popular choices for all types of investors. Both institutional and retail investors have been working to seek gains in the biotech industry. Since the beginning of the year, investors have turn...
-
Can These 4 Biotech Penny Stocks Bring in the Bulls? Biotech penny stocks have been on a big bull run since March of this year. With Covid on the rise around the world, investors are continuing to pay more attention to biotech stocks. Now, not all biotech stocks deal with Covid-rela...
-
OLINVYK is headed for commercial availability, likely by Q1 '21, even though distribution can occur as early as late November following DEA scheduling. Trevena still has a busy 2021 full of catalysts. Revenues could range up to $50-$60 million by late 2022. For further detai...
-
-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day Conference November 16 th Stifel Virtual Healthcare Conference November 1 8 th -- CHESTERBROOK, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ...
Stock Information
MENU
TRVN
TRVN Quote
TRVN Short
TRVN News
TRVN Articles
Get TRVN Alerts
News, Short Squeeze, Breakout and More Instantly...
-
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate ...
-
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a b...
-
-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P 1 receptor without associated lymphopenia IND filing on track for 1H 2021 -- CHESTERBROOK...
x